BACKGROUND: To examine the role of brachytherapy for aged patients 80 or more in the trend of rapidly increasing number. METHODS: We examined the outcomes for elderly patients with node negative oral tongue cancer (T1-3N0M0) treated with brachytherapy. The 21 patients (2 T1, 14 T2, and 5 T3 cases) ranged in age from 80 to 89 years (median 81), and their cancer was pathologically confirmed. All patients underwent definitive radiation therapy, with low dose rate (LDR) Ra-226 brachytherapy (n = 4; median 70Gy), with Ir-192 (n = 12; 70Gy), with Au-198 (n = 1) or with high dose rate (HDR) Ir-192 brachytherapy (n = 4; 60 Gy). Eight patients also underwent external radiotherapy (median 30 Gy). The period of observation ranged from 13 months to 14 years (median 2.5 years). We selected 226 population matched younger counterpart from our medical chart. RESULTS: Definitive radiation therapy was completed for all 21 patients (100%), and acute grade 2-3 mucositis related to the therapy was tolerable. Local control (initial complete response) was attained in 19 of 21 patients (90%). The 2-year and 5-year local control rates were 91%, (100% for T1, 83% for T2 and 80% for T3 tumors after 2 years). These figures was not inferior to that of younger counterpart (82% at 5-year, n.s.). The cause-specific survival rate was 83% and the regional control rate 84% at the 2-years follow-up. However, 12 patients died because of intercurrent diseases or senility, resulting in overall survival rates of 55% at 2 years and 34% at 5 years. CONCLUSION: Age is not a limiting factor for brachytherapy for appropriately selected elderly patients, and brachytherapy achieved good local control with acceptable morbidity.
BACKGROUND: To examine the role of brachytherapy for aged patients 80 or more in the trend of rapidly increasing number. METHODS: We examined the outcomes for elderly patients with node negative oral tongue cancer (T1-3N0M0) treated with brachytherapy. The 21 patients (2 T1, 14 T2, and 5 T3 cases) ranged in age from 80 to 89 years (median 81), and their cancer was pathologically confirmed. All patients underwent definitive radiation therapy, with low dose rate (LDR) Ra-226 brachytherapy (n = 4; median 70Gy), with Ir-192 (n = 12; 70Gy), with Au-198 (n = 1) or with high dose rate (HDR) Ir-192 brachytherapy (n = 4; 60 Gy). Eight patients also underwent external radiotherapy (median 30 Gy). The period of observation ranged from 13 months to 14 years (median 2.5 years). We selected 226 population matched younger counterpart from our medical chart. RESULTS: Definitive radiation therapy was completed for all 21 patients (100%), and acute grade 2-3 mucositis related to the therapy was tolerable. Local control (initial complete response) was attained in 19 of 21 patients (90%). The 2-year and 5-year local control rates were 91%, (100% for T1, 83% for T2 and 80% for T3 tumors after 2 years). These figures was not inferior to that of younger counterpart (82% at 5-year, n.s.). The cause-specific survival rate was 83% and the regional control rate 84% at the 2-years follow-up. However, 12 patients died because of intercurrent diseases or senility, resulting in overall survival rates of 55% at 2 years and 34% at 5 years. CONCLUSION: Age is not a limiting factor for brachytherapy for appropriately selected elderly patients, and brachytherapy achieved good local control with acceptable morbidity.
Authors: J J Mazeron; J M Crook; V Benck; G Marinello; M Martin; M Raynal; E Haddad; R Peynègre; J P Le Bourgeois; W Walop Journal: Int J Radiat Oncol Biol Phys Date: 1990-12 Impact factor: 7.038
Authors: H Yamazaki; T Inoue; K Yoshida; A Imai; Y Yoshioka; E Tanaka; S Shimamoto; S Nakamura; T Inoue; H Nakamura; S Furukawa; K Shimizutani Journal: Int J Radiat Oncol Biol Phys Date: 2001-03-15 Impact factor: 7.038
Authors: M Oguchi; H Ikeda; T Watanabe; N Shikama; T Ohata; Y Okazaki; K Kiyono; S Sone Journal: Int J Radiat Oncol Biol Phys Date: 1998-05-01 Impact factor: 7.038
Authors: T Pignon; J C Horiot; M Bolla; H van Poppel; H Bartelink; F Roelofsen; F Pene; A Gerard; N Einhorn; T D Nguyen; M Vanglabbeke; P Scalliet Journal: Radiother Oncol Date: 1997-02 Impact factor: 6.280
Authors: Jean Bourhis; Jens Overgaard; Hélène Audry; Kian K Ang; Michele Saunders; Jacques Bernier; Jean-Claude Horiot; Aurélie Le Maître; Thomas F Pajak; Michael G Poulsen; Brian O'Sullivan; Werner Dobrowsky; Andrzej Hliniak; Krzysztof Skladowski; John H Hay; Luiz H J Pinto; Carlo Fallai; Karen K Fu; Richard Sylvester; Jean-Pierre Pignon Journal: Lancet Date: 2006-09-02 Impact factor: 79.321